Neuromuscular junction

10 min read Last updated March 21, 2026

Neurophysiology/Physiology context for neuromuscular blocking drugs (NMBAs)

Clinical relevance to anaesthesia

  • NMBAs act at the NMJ: understanding transmission explains onset/offset, fade, potentiation, and reversal.
    • Depolarising: persistent agonism at nicotinic ACh receptor (nAChR) → depolarisation block then desensitisation.
    • Non-depolarising: competitive antagonism at nAChR → reduced end-plate potential (EPP) and safety margin.
  • Monitoring patterns (TOF, tetanus, PTC) reflect presynaptic and postsynaptic physiology.
    • Fade is mainly due to presynaptic nAChR blockade reducing ACh mobilisation during repetitive stimulation.
  • Disease and drugs alter NMJ physiology and NMBA response.
    • Myasthenia gravis: fewer functional postsynaptic nAChRs → very sensitive to non-depolarising NMBAs; resistant to suxamethonium (often).
    • Burns/denervation/immobility: upregulation/extrajunctional spread of nAChRs → resistance to non-depolarising NMBAs; dangerous hyperkalaemia with suxamethonium.

High-yield numbers (useful in vivas)

  • Resting membrane potential (skeletal muscle): around −90 mV.
  • ACh quanta: one vesicle contains ~5,000–10,000 ACh molecules; one nerve impulse releases ~100–300 quanta (order of magnitude).
  • Synaptic cleft width: ~50 nm; NMJ has deep junctional folds increasing receptor density and safety margin.
  • nAChR channel: ligand-gated cation channel; reversal potential ~0 mV; Na+ influx predominates at resting potentials.

Anatomy and organisation of the NMJ

  • Components: motor nerve terminal, synaptic cleft with basal lamina, postsynaptic motor end-plate with junctional folds.
    • Active zones: presynaptic release sites aligned with postsynaptic junctional folds (efficient transmission).
    • Acetylcholinesterase (AChE) concentrated in basal lamina of cleft (rapid termination of ACh action).
  • Receptor distribution: high density of nAChRs at crests of junctional folds; voltage-gated Na+ channels concentrated in depths of folds (trigger AP).
  • nAChR structure: pentameric ligand-gated ion channel.
    • Adult (junctional) muscle nAChR: 2α, β, δ, ε subunits (ε replaces γ after development).
    • Fetal/extrajunctional: 2α, β, δ, γ; longer channel open time → greater K+ efflux risk when widely expressed (e.g., burns/denervation).

Presynaptic events: synthesis, storage, release of ACh

  • ACh synthesis: choline + acetyl-CoA → ACh via choline acetyltransferase (ChAT) in nerve terminal cytoplasm.
    • Choline uptake is rate-limiting (high-affinity, Na+-dependent transporter); choline largely from ACh breakdown.
  • Vesicular storage: ACh transported into vesicles by vesicular ACh transporter (VAChT).
  • Nerve action potential opens presynaptic P/Q-type voltage-gated Ca2+ channels → Ca2+ influx triggers vesicle fusion via SNARE proteins (synaptobrevin/VAMP, syntaxin, SNAP-25).
    • Botulinum toxin cleaves SNARE proteins → reduced ACh release → weakness and profound sensitivity to non-depolarising NMBAs.
    • Mg2+ and aminoglycosides reduce Ca2+-dependent ACh release → potentiate non-depolarising block.
  • Quantal release: ACh released in packets (quanta); miniature end-plate potentials (MEPPs) occur spontaneously without nerve AP.
    • MEPP amplitude reflects postsynaptic sensitivity (receptor number/function); frequency reflects presynaptic release probability.
  • Presynaptic modulation: neuronal nAChRs facilitate ACh mobilisation during repetitive stimulation; blockade contributes to fade with non-depolarising NMBAs.

Postsynaptic events: end-plate potential and muscle action potential

  • ACh binds to two α subunits on muscle nAChR → channel opens → Na+ influx (and K+ efflux) → depolarising end-plate potential (EPP).
  • EPP is a graded potential (not all-or-none) and normally exceeds threshold by a large safety margin.
    • Non-depolarising NMBAs reduce EPP amplitude by reducing the number of available receptors; when EPP fails to reach threshold → no muscle AP → paralysis.
  • Muscle AP initiation: EPP depolarises perijunctional membrane; voltage-gated Na+ channels in junctional folds open → propagated AP along sarcolemma and T-tubules.
  • Depolarising block (suxamethonium): persistent depolarisation inactivates voltage-gated Na+ channels (Phase I) → no propagated AP despite receptor activation.
    • With time/exposure: receptor desensitisation and repolarisation with persistent weakness (Phase II features) → fade may appear and anticholinesterases may partially reverse (unreliably).

Termination of transmission and recovery

  • ACh rapidly hydrolysed by acetylcholinesterase (AChE) to acetate + choline; choline recycled into nerve terminal.
  • Anticholinesterases (e.g., neostigmine): inhibit AChE → increased ACh at NMJ → outcompete non-depolarising NMBAs; also increase muscarinic effects (needs antimuscarinic).
    • Ceiling effect: if profound block (few receptors available), increasing ACh may not restore adequate EPP; reversal best when some recovery present (e.g., TOF count ≥2).
  • Sugammadex: encapsulates aminosteroid NMBAs (rocuronium > vecuronium) in plasma → reduces free drug → gradient pulls drug off receptor (not dependent on AChE).

Excitation–contraction coupling (why NMJ transmission matters)

  • Muscle AP travels down T-tubules → activates dihydropyridine receptor (DHPR, L-type Ca2+ channel) mechanically coupled to ryanodine receptor (RyR1) on sarcoplasmic reticulum → Ca2+ release.
  • Ca2+ binds troponin C → moves tropomyosin → actin–myosin cross-bridge cycling (ATP-dependent) → contraction; relaxation via SERCA reuptake of Ca2+.
  • Malignant hyperthermia relates to abnormal RyR1-mediated Ca2+ release (not a primary NMJ disorder) but clinically linked to anaesthesia drugs used alongside NMBAs.

Safety margin, receptor reserve, and implications for NMBAs

  • NMJ has a large safety margin: more ACh released and more receptors available than needed to trigger a muscle AP.
    • Clinical implication: significant receptor occupancy is required before weakness appears; paralysis typically requires high receptor occupancy by non-depolarising NMBAs (often quoted ~70–95% depending on endpoint).
  • Spare receptors: maximal response can occur without all receptors being occupied; explains why partial receptor blockade may not produce clinical weakness.
  • Myasthenia gravis reduces receptor number → reduced safety margin → weakness and marked sensitivity to competitive antagonists.

Train-of-four fade, tetanus, and post-tetanic count: physiological basis

  • Non-depolarising block: TOF fade and tetanic fade due to impaired mobilisation/release of ACh during repeated stimulation (presynaptic effect) plus postsynaptic competitive antagonism.
  • Post-tetanic facilitation: tetanus increases presynaptic Ca2+ → transiently increases ACh release → temporary improvement in responses (basis of PTC during profound block).
  • Depolarising Phase I block: typically no fade (TOF ratio preserved) because presynaptic mobilisation is relatively intact; Phase II may show fade.

Factors altering NMJ transmission (drug and physiological interactions)

  • Reduce ACh release (potentiate non-depolarising block): Mg2+, aminoglycosides, polymyxins, clindamycin, calcium channel blockers (variable), local anaesthetics (high dose), lithium.
  • Alter postsynaptic sensitivity: volatile agents potentiate non-depolarising block (central and peripheral mechanisms; reduced muscle contractility and NMJ effects).
  • Acid–base/electrolytes: hypokalaemia and hypocalcaemia can increase weakness; hypermagnesaemia reduces release; acidosis may potentiate block (drug- and context-dependent).
  • Temperature: hypothermia prolongs NMBA effect (reduced metabolism/clearance and altered receptor/channel kinetics).

Developmental and pathological receptor changes (key for suxamethonium and resistance)

  • Extrajunctional (fetal-type) nAChRs appear with denervation, burns, immobilisation, upper motor neuron lesions, critical illness myopathy/neuropathy.
    • Consequences: resistance to non-depolarising NMBAs (more receptors); increased K+ efflux with suxamethonium → risk of life-threatening hyperkalaemia.
  • Myotonic dystrophy and other myopathies: unpredictable responses; avoid suxamethonium due to myotonia and potential complications (not classic hyperkalaemia mechanism like burns, but still high risk).
Describe the structure of the neuromuscular junction and the distribution of receptors/ion channels.

Aim: anatomy that explains the safety margin and where NMBAs act.

  • Presynaptic terminal: motor nerve ending with synaptic vesicles containing ACh; active zones aligned with postsynaptic folds.
  • Synaptic cleft: ~50 nm; contains basal lamina rich in acetylcholinesterase (AChE).
  • Postsynaptic end-plate: junctional folds increase surface area.
    • nAChRs concentrated at crests of folds (high receptor density).
    • Voltage-gated Na+ channels concentrated deeper in folds/perijunctional membrane (AP initiation).
  • nAChR is a pentameric ligand-gated cation channel; adult receptor subunits: 2αβδε; fetal/extrajunctional: 2αβδγ.
Explain acetylcholine synthesis, storage, release, and termination at the NMJ, and relate this to drugs used in anaesthesia.

This is a common FRCA viva theme: stepwise physiology + drug interactions.

  • Synthesis: choline + acetyl-CoA → ACh via choline acetyltransferase (ChAT).
    • High-affinity choline uptake is rate-limiting; choline largely derived from ACh breakdown.
  • Storage: ACh loaded into vesicles by VAChT.
  • Release: nerve AP → presynaptic P/Q-type Ca2+ channels open → Ca2+-triggered vesicle fusion via SNARE proteins.
    • Botulinum toxin cleaves SNARE proteins → reduced ACh release → weakness; marked sensitivity to non-depolarising NMBAs.
    • Mg2+ and aminoglycosides reduce Ca2+-dependent release → potentiate non-depolarising block.
  • Termination: ACh hydrolysed by AChE in cleft → acetate + choline; choline recycled.
    • Neostigmine inhibits AChE → increases ACh → reverses competitive (non-depolarising) block; requires antimuscarinic due to muscarinic effects.
What is meant by quantal release and miniature end-plate potentials (MEPPs)? How can this be used to localise pathology to pre- or postsynaptic sites?

Often asked in physiology vivas to test understanding of synaptic transmission.

  • Quantal release: ACh released in discrete packets (quanta), each corresponding to fusion of a single vesicle.
  • MEPP: small spontaneous depolarisation at end-plate due to release of one quantum without a nerve AP.
  • Localisation concept:
    • MEPP frequency reflects presynaptic release probability (reduced in presynaptic disorders).
    • MEPP amplitude reflects postsynaptic receptor number/function (reduced in postsynaptic disorders like myasthenia).
Describe how an end-plate potential (EPP) leads to a muscle action potential and contraction. Where do NMBAs act in this sequence?

A classic integrated question: NMJ → AP → excitation–contraction coupling.

  • ACh binds nAChR → channel opens → Na+ influx/K+ efflux → EPP (graded depolarisation).
  • If EPP reaches threshold, voltage-gated Na+ channels open → propagated muscle AP along sarcolemma and T-tubules.
  • Excitation–contraction coupling: T-tubule depolarisation activates DHPR → RyR1 opens → Ca2+ release from SR → contraction via troponin/tropomyosin.
  • Sites of drug action:
    • Non-depolarising NMBAs competitively antagonise nAChR → reduce EPP amplitude.
    • Suxamethonium agonises nAChR → persistent depolarisation → Na+ channel inactivation (Phase I).
    • Volatile agents and some antibiotics/Mg2+ reduce effective transmission by pre- and postsynaptic mechanisms.
Define the ‘safety margin’ at the NMJ and explain its clinical implications for neuromuscular blockade and myasthenia gravis.

This commonly appears as a short written or viva question.

  • Safety margin: normal NMJ releases more ACh and has more functional receptors than required to reach threshold and trigger a muscle AP.
  • Clinical implications:
    • Considerable receptor occupancy by non-depolarising NMBAs is needed before weakness becomes apparent; paralysis requires high occupancy.
    • Myasthenia gravis reduces available postsynaptic nAChRs → reduced safety margin → weakness and marked sensitivity to non-depolarising NMBAs.
Explain train-of-four (TOF) fade in non-depolarising block. Why is there little/no fade in a Phase I depolarising block?

Frequently tested because it links monitoring to physiology.

  • Non-depolarising block: competitive antagonism reduces postsynaptic response; additionally, blockade of presynaptic facilitatory nAChRs reduces ACh mobilisation during repetitive stimulation → progressively smaller releases → fade.
  • Phase I depolarising block (suxamethonium): receptor is activated (not antagonised) and presynaptic mobilisation is relatively preserved; the problem is persistent depolarisation and Na+ channel inactivation → typically no TOF fade (TOF ratio ~1).
  • Phase II (with prolonged exposure): desensitisation/receptor and channel changes → fade may appear and resembles non-depolarising block.
What is post-tetanic facilitation and how does it allow post-tetanic count (PTC) monitoring during profound block?

Often asked alongside TOF and tetanus.

  • Tetanus causes sustained presynaptic depolarisation → accumulation of Ca2+ in nerve terminal → increased probability of vesicle fusion and ACh release.
  • After tetanus, transiently increased ACh release produces enhanced responses to subsequent single stimuli (post-tetanic facilitation).
  • PTC: during deep non-depolarising block with no TOF response, apply tetanus then count subsequent twitches; higher PTC predicts closer return of TOF responses.
Describe receptor subtypes at the NMJ (adult vs fetal/extrajunctional) and explain why suxamethonium can cause severe hyperkalaemia in burns/denervation.

A recurring FRCA topic: receptor biology linked to a key safety issue.

  • Adult junctional nAChR: 2αβδε; densely packed at end-plate.
  • Fetal/extrajunctional nAChR: 2αβδγ; longer channel open time and different kinetics.
  • Burns/denervation/immobility: upregulation and spread of extrajunctional receptors across muscle membrane.
  • Suxamethonium opens many more channels over a larger area → exaggerated K+ efflux → potentially life-threatening hyperkalaemia.
How do magnesium and aminoglycosides potentiate neuromuscular blockade? Include presynaptic and postsynaptic effects where relevant.

Commonly examined as ‘drug interactions with NMBAs’.

  • Magnesium: competes with Ca2+ at presynaptic voltage-gated Ca2+ channels and reduces Ca2+ entry → reduced ACh release; may also reduce postsynaptic excitability.
  • Aminoglycosides: impair Ca2+-dependent ACh release presynaptically; some also reduce postsynaptic sensitivity at higher concentrations.
  • Clinical result: increased sensitivity to non-depolarising NMBAs and prolonged block; consider dose reduction and careful monitoring.
Compare the physiological basis of Phase I and Phase II block with suxamethonium, and relate this to nerve stimulator findings and reversal.

Frequently asked because it integrates physiology, monitoring, and pharmacology.

  • Phase I: persistent depolarisation at end-plate → voltage-gated Na+ channel inactivation → no propagated AP.
    • Nerve stimulator: reduced twitch height but no fade; TOF ratio ~1; no post-tetanic facilitation.
    • Anticholinesterases: may worsen Phase I block (more ACh adds to depolarisation).
  • Phase II: with prolonged exposure/high dose → repolarisation occurs but receptors become desensitised and transmission resembles non-depolarising block.
    • Nerve stimulator: fade appears; post-tetanic facilitation may be seen.
    • Anticholinesterases: may partially reverse, but response is unpredictable; supportive management and time often required.

0 comments